Results 171 to 180 of about 10,368 (217)

Paradoxical pustular psoriasis following dupilumab therapy for bullous pemphigoid: A case report. [PDF]

JAAD Case Rep
Medina-Figueroa MD, Jiménez-Sacarello I, Sadurní-García M, Martín-García R, Santiago-Vázquez M.   +4 more
europepmc   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study

International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 886-888, August 2026.
Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini   +9 more
wiley   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study. [PDF]

J Clin Med
Gutiérrez-Posso JD, Zabala-López de Maturana A.   +1 more
europepmc   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1344-1358, August 2026.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Dupilumab as a novel therapy for eruptive lichen planus in an Asian patient with metabolic syndrome. [PDF]

Skin Health Dis
Tay RC, Tan E, Tan SH.
europepmc   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1372-1381, August 2026.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner   +14 more
wiley   +1 more source

Use of abrocitinib in severe atopic dermatitis. [PDF]

Rev Assoc Med Bras (1992)
Cruz MFMND, Criado GJ, Ortrolani TA, Martins MDS, Dinato SLME, Silvinato A, Bernardo WM.   +6 more
europepmc   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1359-1371, August 2026.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source